Delta variant now converted to more dangerous Delta +, monoclonal antibodies cocktail may not be affected

Corona's new disaster:  Delta variant now converted to more dangerous Delta +, monoclonal antibodies cocktail may not be affected





Scientists worried Corona's Delta variant is now turning into a more dangerous Delta +
The Delta variant of the Corona wreaked havoc in the country

also read 

Bihar:The mad elephant knocked the young man high from the trunk, causing havoc for 5 consecutive hours.

The Delta variant that wreaked havoc in the country in the second wave of the Corona has now turned into the more dangerous Delta +. Scientists fear that the monoclonal antibody cocktail being given to Corona patients may not be effective on this variant. The English news website Times of India has given this report. Monoclonal antibodies cocktail was approved for emergency use in the country in early May.

also read 

Israel:Three cars plunged into a ditch in the parking area, see CCTV footage

The Times reports that according to Britain's public health organization Public Health England (PHE), the 63 genomes of the Delta variant have come up with a new K417N mutation. According to PHE reports, Delta + was discovered during routine investigations into changes to the Delta variant. As per PHE's latest report on Covid variants, 6 cases of Delta + variant have been reported in India till June 7.

Delta + has been discovered during routine investigations of changes to the Delta variant.

ALSO READ 

Husband and wife riding a bike collided with a car and fell into the air 10 feet, young man died at the scene

Dr. of the Institute of Genomics and Integrative Biology, Delhi. Vinod Sakaria said the biggest concern regarding the K417N mutation is that it has found evidence of antibodies being resistant to cocktails. However, he also said that the frequency of K417N mutations in India is not very high.





Read in Gujarati news 

What is Monoclonal Antibodies Cocktail?
Monoclonal antibodies are composed of the cocktail casirivimab and imdevimab. It is jointly manufactured by pharma company Cipla and Roche India. It was approved in May for emergency use of corona treatment in India. It was approved by the Central Drugs Standards Control Organization (CDSCO) based on data provided for emergency use in the United States and the European Union.